PARI to present eFlow Development at Medical Plastics Seminar; Discussion of a Customizable Platform for New Inhaled Drug Formulations

MONTEREY, CALIFORNIA, November 15, 2005 – Today, Thomas Gallem of the PARI Aerosol Research Institute will present information on the development of the eFlow electronic nebulizer product platform at the Medical Plastics 2005 European Seminar in Copenhagen, Denmark. The presentation, “Platform Strategy for Medical Device Development,” will focus on how eFlow was developed as a customizable platform for new drug formulations and adaptable for current and future medications.

Mr. Gallem will focus on the advantages of the eFlow development approach, which lie in the ability to offer time and cost-efficient customization programs to pharmaceutical partners. These include manufacturing cost controls and higher quantity production possibilities.

The advanced design of eFlow is also a key topic in the presentation. eFlow, an electronic, portable nebulizer, enables a very efficient aerosolization of liquid medications via a vibrating, perforated membrane. Compared to other nebulizer systems, eFlow can produce a dense aerosol bolus of medication, a defined droplet size, and a high proportion of respirable droplets in a shorter amount of time. Its silent mode of operation, small size (it fits in the palm of your hand), light weight, and possibility of battery use make this device extremely user-friendly. The device weighs less than 10 ounces.

PARI continues to work closely with pharmaceutical companies to develop customized drug-device therapies with eFlow. Because eFlow provides the potential for significantly reduced medication doses and treatment times, PARI is in the unique position of helping pharmaceutical companies develop innovative new medication formulations with customized drug-device matching. The potential for creating super-generics, or new uses for proven active ingredients, is also greater with eFlow due to its innovative technology platform.

About PARI

PARI is a leading worldwide manufacturer of fast and efficient aerosol delivery products for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's primary focus is to provide patients with innovative products and services that help control disease. PARI is headquartered in Starnberg, Germany and has offices in the United States, Japan, United Kingdom, and Canada.

Additional information on eFlow is available by contacting Kirsten Ayars at 805-679-7590 or Geoff Hunziker at 831-372-3580. Information on the Medical Plastics 2005 European Seminar is available online at www.hexagon.dk

» Back to Press Releases